Key Takeaways
- Berenberg elevated GSK’s rating from “hold” to “buy” and increased the price target from £20 to £22
- Shares advanced 0.4% to reach £18.62 during morning London trading sessions
- The pharmaceutical company trades at a 23% valuation discount compared to European sector competitors
- GSK secured rights to a trispecific T cell-engager from Chimagen Biosciences in a transaction worth as much as $750 million
- The newly acquired Chimagen asset targets multiple myeloma treatment and is projected to begin Phase 1 clinical trials by 2027
Shares of GSK increased 0.4% to £18.62 during early Tuesday trading in London following an analyst upgrade from Berenberg, which elevated the pharmaceutical manufacturer from “hold” to “buy” while lifting its price objective to £22 from the previous £20 level.
The ratings boost arrives as Berenberg highlighted an increasingly robust late-stage development portfolio and accelerated merger-and-acquisition activity as factors justifying a narrower valuation discount.
The company currently trades at 9.6 times projected 2027 adjusted earnings—representing a 23% discount relative to European pharmaceutical industry peers trading at 12.4 times. According to Berenberg’s analysis, this valuation gap has grown unjustifiably large.
The investment firm observed that external sourcing accounted for 10 of GSK’s 11 innovative Phase 3 candidates. Six of these advanced-stage programs possess the potential to deliver peak annual revenues exceeding £2 billion each.
Berenberg projects GSK will achieve approximately £39 billion in sales by 2031. This estimate surpasses the broader market consensus hovering around £36 billion and approaches GSK’s internal target of exceeding £40 billion.
Key Pipeline Milestones Approaching
Recently commercialized treatments Exdensur and Blenrep are anticipated to drive revenue expansion. Berenberg identifies additional growth opportunities from bepirovirsen, Nuvalent’s lung cancer compounds, and GSK’s oncology antibody-drug conjugates developed alongside Hansoh.
The firm highlighted two imminent regulatory milestones worth monitoring. The FDA’s determination on bepirovirsen for hepatitis B treatment is scheduled for October 26, while a decision regarding neladalkib for second-line ALK-positive lung cancer is expected by November 27.
Additional Phase 3 outcomes and proof-of-concept results are anticipated within the coming year across therapeutic areas including small-cell lung cancer, HIV, asthma, food allergy, and bronchiectasis treatments.
The company’s operational efficiency initiative aims to deliver £1.9 billion in annual cost reductions by 2029. Berenberg believes this program will safeguard research investment levels and maintain profit margins despite anticipated erosion of high-margin oral HIV products beginning in 2028.
The impending patent expiration for dolutegravir represents a recognized challenge. However, Berenberg’s optimistic projections indicate confidence that emerging pipeline products and disciplined cost management will successfully offset this revenue pressure.
Chimagen Transaction Expands Multiple Myeloma Portfolio
In a separate announcement, GSK revealed it has reached an agreement to acquire a trispecific T cell-engager platform from Chimagen Biosciences. The transaction includes worldwide rights and features a total potential consideration reaching $750 million through development achievements and commercial performance milestones.
This T cell-engager technology operates by engaging T cells while simultaneously targeting two distinct tumor-associated antigens. Clinical testing of the asset is anticipated to commence with Phase 1 studies in 2027.
Multiple myeloma ranks as the third most prevalent blood cancer worldwide, with approximately 180,000 new diagnoses recorded annually. While manageable through current therapeutic approaches, the disease remains incurable.
Hesham Abdullah, who leads GSK’s Global Oncology R&D division, stated the transaction “advances GSK’s leadership goals in blood cancer” while providing an additional potential treatment avenue for patients.
This Chimagen arrangement expands upon an established collaboration between both organizations. GSK had previously committed to acquiring CMG1A46, a dual CD19 and CD20-targeted T cell-engager presently undergoing Phase 1 evaluation for B-cell malignancies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
